MRK Meets Primary Endpoint
Merk's Phase 3 ATLAS-UC study of Tulisokibart meets primary endpoint of clinical remission in patients with moderately to severely active UC
Merk Announces Topline Results From Its Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active UC; Study Successfully Met Its Primary Endpoint Of Clinical Remission